Survival and mortality among users and non-users of hydroxyurea with sickle cell disease.

Autor:	de Araujo OM; Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil., Ivo ML; Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil., Ferreira Júnior MA; Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil., Pontes ER; Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil., Bispo IM; Universidade Federal de Mato Grosso do Sul, Três Lagoas, MS, Brazil., de Oliveira EC; Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil.
Jazyk:	English; Portuguese; Spanish; Castilian
Zdroj:	Revista latino-americana de enfermagem [Rev Lat Am Enfermagem] 2015 Jan-Feb; Vol. 23 (1), pp. 67-73.
DOI:	10.1590/0104-1169.3385.2526
Abstrakt:	Objective: to estimate survival, mortality and cause of death among users or not of hydroxyurea with sickle cell disease. Method: cohort study with retrospective data collection, from 1980 to 2010 of patients receiving inpatient treatment in two Brazilian public hospitals. The survival probability was determined using the Kaplan-Meier estimator, survival calculations (SPSS version 10.0), comparison between survival curves, using the log rank method. The level of significance was p=0.05. Results: of 63 patients, 87% had sickle cell anemia, with 39 using hydroxyurea, with a mean time of use of the drug of 20.0±10.0 years and a mean dose of 17.37±5.4 to 20.94±7.2 mg/kg/day, raising the fetal hemoglobin. In the comparison between those using hydroxyurea and those not, the survival curve was greater among the users (p=0.014). A total of 10 deaths occurred, with a mean age of 28.1 years old, and with Acute Respiratory Failure as the main cause. Conclusion: the survival curve is greater among the users of hydroxyurea. The results indicate the importance of the nurse incorporating therapeutic advances of hydroxyurea in her care actions.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu